北京大学人民医院皮肤科主任医师，副教授，硕士生导师。 擅长各种免疫性皮肤病，银屑病及银屑病关节炎，过敏性皮肤病（湿疹、特应性皮炎），痤疮等美容皮肤病。毕业于北京医科大学医疗系，从事皮肤病临床、教学和研究近40年，有着丰富的临床诊疗经验。 主要社会兼职有：亚洲银屑病理事会（ASP）理事。海峡两岸医药卫生交流协会银屑病专委会副主任委员、共病学组副组长。中国康复医学会皮肤病专委会常委、银屑病组副组长。海峡两岸医药卫生交流协会风湿免疫专委会银屑病关节炎学组副组长。中国医师协会银屑病学组委员。中华医学会皮肤性病委员会美容学组及银屑病研究协作组委员。中国食品药品监督管理局评审专家。 近20年来，参与主持银屑病、特应性皮炎等多种药物临床研究数十项（包括1.1类新药苯烯莫德软膏，阿达木单抗，司库奇尤单抗，枸橼酸托法替布（Tofacitinib），TYK2，及度普利尤单抗等），并在近年来对银屑病患者代谢共病（包括尿酸）及生物制剂对其的影响，银屑病关节炎早期识别的生物标志物，矛盾银屑病，银屑病合并2型炎症性疾病等有深入研究，在银屑病及共病的临床及转化研究方面在中国有较高的影响。以第一作者或责任作者发表相关论文100余篇，参与著书8部，参与银屑病相关指南及专家共识4篇，获得国家自然基金，985基金等。 代表性文章： 1.Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017 Jan 31（1）. 89-95. 2.Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis。Chinese Medical Journal 2020;133(22)：2665-73. 3.Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, Zheng J, Zhang FR, Yu JB, Yang S, Li FQ, Xiao SX, Sun QN, Xu JH, Gao XH, Fang H, Gao TW, Hao F, Liu QZ, Tu YT, Li RY, Wang BX, Deng DQ, Zheng QS, Liu HX, Zhang JZ. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J 2020; 133(24)：2905-2909. 4.Cai L, Zhang JZ, Zheng M, Zhang SF, Patekar M. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.. Chin Med J 2021; 134(21)：2629-2631. 5.Cai L. Li LF. Cheng H. Ding YF. Biao ZS. Zhang SF. Geng SM. Liu QZ. Fang H. Song ZQ. Lu Y. Li SS. Guo Q. Tao J. He L. Gu J. Yang QP. Han XP. Gao XH. Deng DQ. Li SQ. Wang QY. Zhu J. Zhang JZ. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther; 2022 Jan.39（1）：583-597. 6.Zhao Z, Cai L(通讯作者), Zhang S, Zhang H, Liu XY, Li CL, Zhao Y, Zhang JZ. Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis. Original Article Chin Med J 2022; 135(12) 1438-1443.(IF: 6.133 ). 7.Zhang S, Cai L(通讯作者), Zhang H, Zhao Z, Liu XY, Zhao Y, Zhang JZ. Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis. Chin Med J 2022; 135(18)2248-2250. (IF: 6.133 ). 8.Liu Xiaoyang, Zhao Yan，Mu Zhanglei，Jia Yuan，Liu Chen, Zhang Jianzhong，Cai Lin(通讯作者).The Combination of IL-6, PLR and Nail Psoriasis: Screen for the Early Diagnosis of Psoriatic Arthritis. Clinical, Cosmetic and Investigational Dermatology 2023:16 1703–1713

亚洲银屑病理事会（ASP）理事； 海峡两岸医药卫生交流协会银屑病学专委会副主任委员、共病学组副组长； 中国康复医学会皮肤病专委会常委、银屑病组副组长； 海峡两岸医药卫生交流协会风湿免疫专委会银屑病关节炎学组副组长； 中国医师协会银屑病学组委员； 中华医学会皮肤性病委员会美容学组、银屑病研究协作组委员。 中国食品药品监督管理局评审专家。

代表性文章： 1.Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017 Jan 31（1）. 89-95. 2.Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis。Chinese Medical Journal 2020;133(22)：2665-73. 3.Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, Zheng J, Zhang FR, Yu JB, Yang S, Li FQ, Xiao SX, Sun QN, Xu JH, Gao XH, Fang H, Gao TW, Hao F, Liu QZ, Tu YT, Li RY, Wang BX, Deng DQ, Zheng QS, Liu HX, Zhang JZ. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J 2020; 133(24)：2905-2909. 4.Cai L, Zhang JZ, Zheng M, Zhang SF, Patekar M. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.. Chin Med J 2021; 134(21)：2629-2631. 5.Cai L. Li LF. Cheng H. Ding YF. Biao ZS. Zhang SF. Geng SM. Liu QZ. Fang H. Song ZQ. Lu Y. Li SS. Guo Q. Tao J. He L. Gu J. Yang QP. Han XP. Gao XH. Deng DQ. Li SQ. Wang QY. Zhu J. Zhang JZ. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther; 2022 Jan.39（1）：583-597. 6.Zhao Z, Cai L(通讯作者), Zhang S, Zhang H, Liu XY, Li CL, Zhao Y, Zhang JZ. Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis. Original Article Chin Med J 2022; 135(12) 1438-1443.(IF: 6.133 ). 7.Zhang S, Cai L(通讯作者), Zhang H, Zhao Z, Liu XY, Zhao Y, Zhang JZ. Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis. Chin Med J 2022; 135(18)2248-2250. (IF: 6.133 ). 8.Liu Xiaoyang, Zhao Yan，Mu Zhanglei，Jia Yuan，Liu Chen, Zhang Jianzhong，Cai Lin(通讯作者).The Combination of IL-6, PLR and Nail Psoriasis: Screen for the Early Diagnosis of Psoriatic Arthritis. Clinical, Cosmetic and Investigational Dermatology 2023:16 1703–1713

临床医师奖、优秀教师奖及人民医院优秀员工